BCPC logo

BALCHEM CORP

BCPCNASDAQ
πŸ† #1222 by market capEarnings Feb 18 Β· PreUS Equity
$166.25β–Ό $2.60 (βˆ’1.54%)
Pre-market Β· at close
πŸ””
Track BCPC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.5%
7dβ–Ό 4.1%
14dβ–Ό 2.6%
30dβ–Ό 0.6%
ytdβ–² 8.3%
1yβ–² 8.2%
🏦Market Cap
$5.28B
Small Cap
πŸ“ˆRevenue Growth (YoY)
9.4%
Slowing
πŸ“ŠGross Margin
36.5%
Healthy
πŸ’΅FCF Margin
16.1%
Healthy
βš–οΈP/S Ratio
4.8x
Fair
Otter Score
72
Strong

Trading Snapshot

Day Range
$165.97 – $170.40
52-Week Range
$147.18 – $183.90
Volume (shares)
10,118
Avg Volume (shares)
β€”
Shares Outstanding
31.8M
Next Earnings
2027-02-18

Fundamentals Snapshot

Annual Revenue
$1.04B
Last Q Revenue
$291M
P/E Ratio
31.1
P/S Ratio
4.8x
EPS (TTM)
$5.31
Dividend Yield
0.58%
Dilution (1yr)
βˆ’0.7%
BCPC logo

BALCHEM CORP

BCPC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.0Bβ–² +8.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
35.7%β–² +1.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$218Mβ–² +19.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$173Mβ–² +18.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
32.3Mβ–Ό βˆ’0.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$117Mβ–² +$41M YoY
StockOtter Β· stockotter.space

About BALCHEM CORP

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.